Close_icon
Enquiry IconContact Us
CMI Logo

Acute bacterial skin and skin structure infections (ABSSSI) are the type of skin and soft tissue infections that affect the epidermis, dermis, and subcutaneous tissues. The U.S. FDA defines ABSSSI as lesions with cellulitis/erysipelas, wound infections, and major cutaneous abscesses occurring in a minimum surface area of 75 cm2. Pathogens such as Methicillin sensitive Staphylococcus aureus (MSSA), Methicillin resistant Staphylococcus aureus (MRSA), Beta-hemolytic Streptococcus, Escherichia coli, Enterococcus faecalis, and Pseudomonas aeruginosa are the major causes of ABSSSI. This infection is difficult to treat due to increasing prevalence of drug resistant strains, especially in Staphylococcus spp. and Enterococcus spp. The ABSSSI market is expected to witness moderate growth owing to the increasing number of patients suffering from skin infections and large number of pipeline products, which are expected to receive approval during the forecast period.

North America and Europe Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market – Impact of Coronavirus (COVID-19) Pandemic

Acute bacterial skin and skin structure infections (ABSSSI) antibiotics treatment is required for majority of patients with severe bacterial skin infection and the treatment might be delayed due to the pandemic. Although, during the COVID-19 pandemic, the antibiotic treatment of ABSSSI patients is often postponed or even cancelled due to the unavailability of ABSSSI antibiotics and irregular supply and transportation of products. Moreover, according to a study published in the Antimicrobial Agents and Chemotherapy journal, the monthly use of antibiotic therapy from March through June 2020 decreased by 151.5% per month compared with January 2018 through February 2020 - a 6.5% monthly reduction in use of antibiotics.

The North America and Europe acute bacterial skin and skin structure infections (ABSSSI) market is estimated to be valued at US$ 1,283.8 million in 2020 and is expected to exhibit a CAGR of 3.9% during the forecast period (2020-2027).

Figure 1. North America and Europe Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market Share (%) Analysis, By Technology, 2020 & 2027

North America and Europe Acute Bacterial Skin and Skin Structure Infections  | Coherent Market Insights

Increasing research and development activities are expected to boost growth of the North America and Europe Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market.

The major driver for the growth of the North America and Europe acute bacterial skin and skin structure infections (ABSSSI) market is research and development of products and novel treatments by pharmaceutical and biopharmaceutical companies. For instance, in August 2019, Basilea Pharmaceutica Ltd. announced positive topline results for the phase 3 TARGET study, evaluating ceftobiprole in the treatment of patients with acute bacterial skin and skin structure infections (ABSSSI). Ceftobiprole medocaril, is a cephalosporin antibiotic for intravenous administration with rapid bactericidal activity against a wide range of Gram-positive and Gram-negative bacteria. This includes methicillin-susceptible and resistant Staphylococcus aureus (MSSA, MRSA) and susceptible Pseudomonas spp. Ceftobiprole is currently in phase 3 clinical development for a potential registration in the U.S., with a completed study in acute bacterial skin and skin structure infections (ABSSSI) and an ongoing study in Staphylococcus aureus bacteremia (SAB).

Furthermore, several key players in the market are focused on obtaining product approvals and launching them in the market to provide better treatment options for ABSSSI. This is expected to significantly drive growth of the North America and Europe ABSSSIs market in near future. For instance, in October 2018, Paratek Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved NUZYRA (omadacycline) for the treatment of adults with community-acquired bacterial pneumonia (CABP) and acute skin and skin structure infections (ABSSSI). NUZYRA, a modernized tetracycline, is a once-daily IV and oral antibiotic that exhibits activity across a spectrum of bacteria, including Gram-positive, Gram-negative, atypicals, and drug resistant strains.

request-sample

North America and Europe Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market Report Coverage

Report Coverage Details
Base Year: 2019 Market Size in 2020: US$ 1,283.8 Mn
Historical Data for: 2016 to 2019 Forecast Period: 2020 to 2027
Forecast Period 2020 to 2027 CAGR:

3.9%

2027 Value Projection: US$ 1,680.7 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
Segments covered:
  • By Drug Type:
    • Oral & Parenteral Antibiotics: Vancomycin, Linezolid, Clindamycin, Ceftaroline, Daptomycin, Dalbavancin, Tedizolid, Others.
    • Topical Antibiotics: Hydrogen Peroxide, Fusidic Acid, Mupirocin, Retapamulin, Povidone-Iodine.
  • By Infection Type: Hospital Acquired ABSSSI, Community Acquired ABSSSI.
  • By Route of Administration: Oral, Parenteral, Topical.
  • By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies.
Companies covered:

Merck & Co., Inc., Pfizer Inc., GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., Paratek Pharmaceuticals, Inc., Melinta Therapeutics, Inc., Arrevus, Inc., AbbVie Inc., Aurobindo Pharma Ltd., Amneal Pharmaceuticals LLC, and Sun Pharmaceutical Industries Ltd.

Growth Drivers:
  • Increasing research and development activities
  • Rising number of product approvals from regulatory bodies
Restraints & Challenges:
  • Patent Expiration And Antibiotic Resistance

North America and Europe Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market – Restraints

Patent expiration of ABSSSI antibiotic drugs is a major factor restraining growth of the North America and Europe acute bacterial skin and skin structure infections (ABSSSI) market. According to the Centers for Disease Control and Prevention, the World Health Organization, and U.S. and European governments, patent expiration leads to the production of low priced and low cost generic drugs are easily accessible which leads to their overuse and misuse. Bacteria evolve when subjected to selective pressure and multi-antibiotic resistance in organisms as ubiquitous as Escherichia coli and Staphylococcus aureus has been observed. Furthermore, patent expiry has led low cost generic drugs to dominate the market and misuse of drugs.

North America and Europe Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market – Regional Analysis

North America is expected to hold dominant position in the North America and Europe Acute Bacterial Skin and Skin Structure Infections (ABSSSI) market. Launch of products by key players is propelling growth of the North America acute bacterial skin and skin structure infections (ABSSSI) market. For instance, in June 2018, Melinta Therapeutics, Inc., a commercial-stage company focused on developing and commercializing novel antibiotics to treat serious bacterial infections, announced the U.S. launch of intravenous and oral formulations of Baxdela (delafloxacin) for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI) caused by designated susceptible bacteria.

Europe is expected to witness significant growth in the market due to increasing number of product approvals. For instance, in August 2016, Cardiome Pharma Corp. announced that XYDALBA (dalbavancin) has been approved by the European Medicines Agency (EMA) for administration as a single, 30 minute, 1500 mg infusion (three 500mg vials) as a treatment for Acute Bacterial Skin and Skin Structure Infections (ABSSSIs) in adults.

Figure 2. North America and Europe Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market Value (US$ Mn) & Y-o-Y Growth (%), 2016-2027

North America and Europe Acute Bacterial Skin and Skin Structure Infections  | Coherent Market Insights

North America and Europe Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market - Competitive Landscape

Key players operating in the North America and Europe Acute Bacterial Skin and Skin Structure Infections (ABSSSI) market are Merck & Co., Inc., Pfizer Inc., GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., Paratek Pharmaceuticals, Inc., Melinta Therapeutics, Inc., Arrevus, Inc., AbbVie Inc., Aurobindo Pharma Ltd., Amneal Pharmaceuticals LLC, and Sun Pharmaceutical Industries Ltd.

Infoimg

Acute bacterial skin and skin structure infections (ABSSSI) are the skin and soft tissue infections that affect the epidermis, dermis, and subcutaneous tissues. The U.S. FDA defines ABSSSI as lesions with cellulitis/erysipelas, wound infections, and major cutaneous abscesses occurring in a minimum surface area of 75 cm2. Increasing number of ambulatory patients seeking treatment for skin and skin structure infections will further propel growth of the ABSSSI market. For instance, according to Decision Resource Group, in 2014, 11% of 2.7 million hospital admissions for ABSSSI were pediatric patients. The increasing pediatric patient pool is targeted by the manufacturers to enhance its product portfolio with pediatric specific products. For instance, in 2016, Allergan plc received US FDA approval for its supplemental New Drug Application (sNDA) for Teflaro, for ABSSSI indication in pediatric.

Market Dynamics

The major market driver for growth of North America and Europe Acute Bacterial Skin and Skin Structure Infections (ABSSSI) market is increasing research and development activities by pharmaceutical and biopharmaceutical companies to develop new products and novel treatment. For instance, in 2017, Cempra announced promising data from the phase 3 trial of Fusidic acid for the treatment of ABSSSI. In same year, Melinta Therapeutics received U.S. FDA for its product Baxdela, a delafloxacin based ABSSSI medicine, available in both intravenous and oral formulations. Moreover, in 2018, Fresenius Kabi received U.S. FDA approval for new drug application of daptomycin, a lipopeptide class of antibacterial drug, in injectable form for complicated skin and skin structure infections (cSSSI) caused by susceptible Gram-positive bacteria such as Staphylococcus aureus, Streptococcus pyogenes, Streptococcus agalactlae etc.

However, misuse of drugs causes antibiotic resistance which is a major factor hindering growth of the North America and Europe acute bacterial skin and skin structure infections (ABSSSI) market. For example, according to the Centers for Disease Control and Prevention data has shown that treatment indication, choice of agent, or duration of antibiotic therapy is incorrect in 30-50% of cases. Moreover, 30-60% of antibiotics prescribed in intensive care units (ICUs) have been found to be unnecessary, inappropriate, or suboptimal.

Key features of the study:

  • This report provides in-depth analysis of the North America and Europe acute bacterial skin and skin structure infections (ABSSSI) market, market size (US$ Mn), and compound annual growth rate (CAGR (%)) for the forecast period: 2020-2027, considering 2019 as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by leading players
  • It profiles key players in the North America and Europe acute bacterial skin and skin structure infections (ABSSSI) market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
  • Key players covered as a part of this study are Merck & Co., Inc., Pfizer Inc., GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., Paratek Pharmaceuticals, Inc., Melinta Therapeutics, Inc., Arrevus, Inc., AbbVie Inc., Aurobindo Pharma Ltd., Amneal Pharmaceuticals LLC, and Sun Pharmaceutical Industries Ltd.
  • Insights from this report would allow marketers and management authorities of companies to make informed decisions with respect to future product launches, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
  • The North America and Europe acute bacterial skin and skin structure infections (ABSSSI) market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for North America and Europe acute bacterial skin and skin structure infections (ABSSSI) market, research and consulting firms, new entrants, and financial analysts.

Detailed Segmentation:

  • North America and Europe Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market, By Drug Type:
    • Oral & Parenteral Antibiotics
      • Vancomycin
      • Linezolid
      • Clindamycin
      • Ceftaroline
      • Daptomycin
      • Dalbavancin
      • Tedizolid
      • Others
    • Topical Antibiotics
      • Hydrogen Peroxide
      • Fusidic Acid
      • Mupirocin
      • Retapamulin
      • Povidone-Iodine
  • North America and Europe Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market, By Infection Type:
    • Hospital Acquired ABSSSI
    • Community Acquired ABSSSI
  • North America and Europe Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market, By Route of Administration:
    • Oral
    • Parenteral
    • Topical
  • North America and Europe Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • North America and Europe Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market, By Region:
    • North America
      • By Country:
        • U.S.
          • By Drug Type:
            • Oral & Parenteral Antibiotics
              • Vancomycin
              • Linezolid
              • Clindamycin
              • Ceftaroline
              • Daptomycin
              • Dalbavancin
              • Tedizolid
              • Others
            • Topical Antibiotics
              • Hydrogen Peroxide
              • Fusidic Acid
              • Mupirocin
              • Retapamulin
              • Povidone-Iodine
          • By Infection Type:
            • Hospital Acquired ABSSSI
            • Community Acquired ABSSSI
          • By Route of Administration:
            • Oral
            • Parenteral
            • Topical
          • By Distribution Channel:
            • Hospital Pharmacies
            • Retail Pharmacies
            • Online Pharmacies
        • Canada
          • By Drug Type:
            • Oral & Parenteral Antibiotics
              • Vancomycin
              • Linezolid
              • Clindamycin
              • Ceftaroline
              • Daptomycin
              • Dalbavancin
              • Tedizolid
              • Others
            • Topical Antibiotics
              • Hydrogen Peroxide
              • Fusidic Acid
              • Mupirocin
              • Retapamulin
              • Povidone-Iodine
          • By Infection Type:
            • Hospital Acquired ABSSSI
            • Community Acquired ABSSSI
          • By Route of Administration:
            • Oral
            • Parenteral
            • Topical
          • By Distribution Channel:
            • Hospital Pharmacies
            • Retail Pharmacies
            • Online Pharmacies
    • Europe
      • By Country:
        • U.K.
          • By Drug Type:
            • Oral & Parenteral Antibiotics
              • Vancomycin
              • Linezolid
              • Clindamycin
              • Ceftaroline
              • Daptomycin
              • Dalbavancin
              • Tedizolid
              • Others
            • Topical Antibiotics
              • Hydrogen Peroxide
              • Fusidic Acid
              • Mupirocin
              • Retapamulin
              • Povidone-Iodine
          • By Infection Type:
            • Hospital Acquired ABSSSI
            • Community Acquired ABSSSI
          • By Route of Administration:
            • Oral
            • Parenteral
            • Topical
          • By Distribution Channel:
            • Hospital Pharmacies
            • Retail Pharmacies
            • Online Pharmacies
        • Germany
          • By Drug Type:
            • Oral & Parenteral Antibiotics
              • Vancomycin
              • Linezolid
              • Clindamycin
              • Ceftaroline
              • Daptomycin
              • Dalbavancin
              • Tedizolid
              • Others
            • Topical Antibiotics
              • Hydrogen Peroxide
              • Fusidic Acid
              • Mupirocin
              • Retapamulin
              • Povidone-Iodine
          • By Infection Type:
            • Hospital Acquired ABSSSI
            • Community Acquired ABSSSI
          • By Route of Administration:
            • Oral
            • Parenteral
            • Topical
          • By Distribution Channel:
            • Hospital Pharmacies
            • Retail Pharmacies
            • Online Pharmacies
        • Italy
          • By Drug Type:
            • Oral & Parenteral Antibiotics
              • Vancomycin
              • Linezolid
              • Clindamycin
              • Ceftaroline
              • Daptomycin
              • Dalbavancin
              • Tedizolid
              • Others
            • Topical Antibiotics
              • Hydrogen Peroxide
              • Fusidic Acid
              • Mupirocin
              • Retapamulin
              • Povidone-Iodine
          • By Infection Type:
            • Hospital Acquired ABSSSI
            • Community Acquired ABSSSI
          • By Route of Administration:
            • Oral
            • Parenteral
            • Topical
          • By Distribution Channel:
            • Hospital Pharmacies
            • Retail Pharmacies
            • Online Pharmacies
        • Spain
          • By Drug Type:
            • Oral & Parenteral Antibiotics
              • Vancomycin
              • Linezolid
              • Clindamycin
              • Ceftaroline
              • Daptomycin
              • Dalbavancin
              • Tedizolid
              • Others
            • Topical Antibiotics
              • Hydrogen Peroxide
              • Fusidic Acid
              • Mupirocin
              • Retapamulin
              • Povidone-Iodine
          • By Infection Type:
            • Hospital Acquired ABSSSI
            • Community Acquired ABSSSI
          • By Route of Administration:
            • Oral
            • Parenteral
            • Topical
          • By Distribution Channel:
            • Hospital Pharmacies
            • Retail Pharmacies
            • Online Pharmacies
        • France
          • By Drug Type:
            • Oral & Parenteral Antibiotics
              • Vancomycin
              • Linezolid
              • Clindamycin
              • Ceftaroline
              • Daptomycin
              • Dalbavancin
              • Tedizolid
              • Others
            • Topical Antibiotics
              • Hydrogen Peroxide
              • Fusidic Acid
              • Mupirocin
              • Retapamulin
              • Povidone-Iodine
          • By Infection Type:
            • Hospital Acquired ABSSSI
            • Community Acquired ABSSSI
          • By Route of Administration:
            • Oral
            • Parenteral
            • Topical
          • By Distribution Channel:
            • Hospital Pharmacies
            • Retail Pharmacies
            • Online Pharmacies
        • Russia
          • By Drug Type:
            • Oral & Parenteral Antibiotics
              • Vancomycin
              • Linezolid
              • Clindamycin
              • Ceftaroline
              • Daptomycin
              • Dalbavancin
              • Tedizolid
              • Others
            • Topical Antibiotics
              • Hydrogen Peroxide
              • Fusidic Acid
              • Mupirocin
              • Retapamulin
              • Povidone-Iodine
          • By Infection Type:
            • Hospital Acquired ABSSSI
            • Community Acquired ABSSSI
          • By Route of Administration:
            • Oral
            • Parenteral
            • Topical
          • By Distribution Channel:
            • Hospital Pharmacies
            • Retail Pharmacies
            • Online Pharmacies
        • Rest of Europe
          • By Drug Type:
            • Oral & Parenteral Antibiotics
              • Vancomycin
              • Linezolid
              • Clindamycin
              • Ceftaroline
              • Daptomycin
              • Dalbavancin
              • Tedizolid
              • Others
            • Topical Antibiotics
              • Hydrogen Peroxide
              • Fusidic Acid
              • Mupirocin
              • Retapamulin
              • Povidone-Iodine
          • By Infection Type:
            • Hospital Acquired ABSSSI
            • Community Acquired ABSSSI
          • By Route of Administration:
            • Oral
            • Parenteral
            • Topical
          • By Distribution Channel:
            • Hospital Pharmacies
            • Retail Pharmacies
            • Online Pharmacies
  • Company Profiles
    • Merck & Co., Inc.*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Strategies
    • Pfizer Inc.
    • GlaxoSmithKline plc.
    • Teva Pharmaceutical Industries Ltd.
    • Paratek Pharmaceuticals, Inc.
    • Melinta Therapeutics, Inc.
    • Arrevus, Inc.
    • AbbVie Inc.
    • Aurobindo Pharma Ltd.
    • Amneal Pharmaceuticals LLC
    • Sun Pharmaceutical Industries Ltd.

“*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Overview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Drug Type
      • Market Snippet, By Infection Type
      • Market Snippet, By Route of Administration
      • Market Snippet, By Distribution Channel
      • Market Snippet, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Drivers
    • Restraints
    • Market Opportunities
    • Impact Analysis
    • Regulatory Scenario
    • Drug Approval Process In The U.S.
    • Regulatory Hurdles
    • U.S. FDA Guidance For ABSSSI Trials
    • Pipeline Analysis
    • Reimbursement Scenario
    • New Product Launches & Approvals
    • Key Developments
    • Epidemiology
    • Government Initiatives and Investments
    • PEST Analysis
  4. Impact of COVID-19 on North America & Europe Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Market
    • Supply Side And Demand Side Analysis
    • Overall Impact
    • Impact on Research and Development
  5. North America & Europe Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Market, By Drug Type, 2016 – 2027, (US$ Million)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Oral & Parenteral Antibiotics       
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
        • Vancomycin
        • Linezolid
        • Clindamycin
        • Ceftaroline
        • Daptomycin
        • Dalbavancin
        • Tedizolid
        • Others
    • Topical Antibiotics
      •  Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
        • Hydrogen Peroxide
        • Fusidic Acid
        • Mupirocin
        • Retapamulin
        • Povidone-Iodine
  6. North America & Europe Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Market, By Infection Type, 2016 – 2027, (US$ Million)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Hospital Acquired ABSSSI
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Community Acquired ABSSSI
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
  7. North America & Europe Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Market, By Route of Administration, 2016 – 2027, (US$ Million)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Oral
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Parenteral
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Topical
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
  8. North America & Europe Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Market, By Distribution Channel, 2016 – 2027, (US$ Million)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Hospital Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Retail Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Online Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
  9. North America & Europe Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Market, By Region, 2016 – 2027, (US$ Million)
    • Introduction
      • Market Share Analysis, By Region, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, By Region, 2017 – 2027
      • Regional Trends
    • North America
      • Market Size and Forecast, By Drug Type, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Infection Type, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Route of Administration, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
        • U.S.
          • Market Size and Forecast, By Drug Type, 2016 – 2027, (US$ Million)
          • Market Size and Forecast, By Infection Type, 2016 – 2027, (US$ Million)
          • Market Size and Forecast, By Route of Administration, 2016 – 2027, (US$ Million)
          • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Million)
        • Canada
          • Market Size and Forecast, By Drug Type, 2016 – 2027, (US$ Million)
          • Market Size and Forecast, By Infection Type, 2016 – 2027, (US$ Million)
          • Market Size and Forecast, By Route of Administration, 2016 – 2027, (US$ Million)
          • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Million)
    • Europe
      • Market Size and Forecast, By Drug Type, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Infection Type, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Route of Administration, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
        • U.K.
          • Market Size and Forecast, By Drug Type, 2016 – 2027, (US$ Million)
          • Market Size and Forecast, By Infection Type, 2016 – 2027, (US$ Million)
          • Market Size and Forecast, By Route of Administration, 2016 – 2027, (US$ Million)
          • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Million)
        • Germany
          • Market Size and Forecast, By Drug Type, 2016 – 2027, (US$ Million)
          • Market Size and Forecast, By Infection Type, 2016 – 2027, (US$ Million)
          • Market Size and Forecast, By Route of Administration, 2016 – 2027, (US$ Million)
          • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Million)
        • Italy
          • Market Size and Forecast, By Drug Type, 2016 – 2027, (US$ Million)
          • Market Size and Forecast, By Infection Type, 2016 – 2027, (US$ Million)
          • Market Size and Forecast, By Route of Administration, 2016 – 2027, (US$ Million)
          • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Million)
        • France
          • Market Size and Forecast, By Drug Type, 2016 – 2027, (US$ Million)
          • Market Size and Forecast, By Infection Type, 2016 – 2027, (US$ Million)
          • Market Size and Forecast, By Route of Administration, 2016 – 2027, (US$ Million)
          • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Million)
        • Spain
          • Market Size and Forecast, By Drug Type, 2016 – 2027, (US$ Million)
          • Market Size and Forecast, By Infection Type, 2016 – 2027, (US$ Million)
          • Market Size and Forecast, By Route of Administration, 2016 – 2027, (US$ Million)
          • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Million)
        • Russia
          • Market Size and Forecast, By Drug Type, 2016 – 2027, (US$ Million)
          • Market Size and Forecast, By Infection Type, 2016 – 2027, (US$ Million)
          • Market Size and Forecast, By Route of Administration, 2016 – 2027, (US$ Million)
          • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Million)
        • Rest of Europe
          • Market Size and Forecast, By Drug Type, 2016 – 2027, (US$ Million)
          • Market Size and Forecast, By Infection Type, 2016 – 2027, (US$ Million)
          • Market Size and Forecast, By Route of Administration, 2016 – 2027, (US$ Million)
          • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Million)
  10. Competitive Landscape
    • Company Profiles
      • Merck & Co., Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Pfizer Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • GlaxoSmithKline plc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Teva Pharmaceutical Industries Ltd.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Paratek Pharmaceuticals, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Melinta Therapeutics, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Arrevus, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • AbbVie Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Aurobindo Pharma Ltd.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Amneal Pharmaceuticals LLC
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Sun Pharmaceutical Industries Ltd.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
  11. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 61 market data tables and 49 figures on "North America & Europe Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market” - Forecast to 2027”

Research Methodology

Coherent Market Insights followsa comprehensive research methodology focused on providing the most precise market analysis. The company leverages a data triangulation model which helps company to gauge the market dynamics and provide accurate estimates. Key components of the research methodologies followed for all our market reports include:

  • Primary Research (Trade Surveys and Experts Interviews)
  • Desk Research
  • Proprietor Data Analytics Model

In addition to this, Coherent Market Insights has access to a wide range of the regional and global reputed paid data bases, which helps the company to figure out the regional and global market trends and dynamics. The company analyses the industry from the 360 Degree Perspective i.e. from the Supply Side and Demand Side which enables us to provide granular details of the entire ecosystem for each study. Finally, a Top-Down approach and Bottom-Up approach is followed to arrive at ultimate research findings.


Data Triangulation Methodology | Coherent Market Insights

Coherent Market Insights desk research is based on a principle set of research techniques:

  • National level desk research: It Includes research analysis of regional players, regional regulatory bodies, regional trade associations, and regional organization.
  • Multinational level desk research: The research team keeps a track of multinational players, global regulatory bodies, global trade associations, and global organization.

Coherent Market Insights has a large amount of in-house repository of industry database. This is leveraged as a burner for initiating a new research study. Key secondary sources include:

  • Governmental bodies, National and international social welfare institutions, and organizations creating economic policies among others.
  • Trade association, National and international media and trade press.
  • Company Annual reports, SEC filings, Corporate Presentations, press release, news, and specification sheet of manufacturers, system integrators, brick and mortar - distributors and retailers, and third party online commerce players.
  • Scientific journals, and other technical magazines and whitepapers.

Market Analysis | Coherent Market Insights

Preliminary Data Mining

The raw data is obtained through the secondary findings, in house repositories, and trade surveys. It is then filtered to ensure that the relevant information including industry dynamics, trends, and outlook is retained for further research process.

Data Standardization

Holistic approach is used to ensure that the granular and uncommon parameters are taken into consideration to ensure accurate results. The information from the paid databases are further combined to the raw data in order to standardize it.

Coherent Statistical model

We arrive at our final research findings through simulation models. Coherent Data Analytics Model is a statistical tool that helps company to forecast market estimates. Few of the parameters considered as a part of the statistical model include:

  • Micro-economic indicators
  • Macro-economic indicators
  • Environmental indicators
  • Socio-political indicators
  • Technology indicators

Data Processing

Once the findings are derived from the statistical model, large volume of data is process to confirm accurate research results. Data analytics and processing tools are adopted to process large chunk of collected informative data. In case, a client customizes the study during the process, the research finding till then are benchmarked, and the process for new research requirement is initiated again.

Data Validation

This is the most crucial stage of the research process. Primary Interviews are conducted to validate the data and analysis. This helps in achieving the following purposes:

  • It provides first-hand information on the market dynamics, outlook, and growth parameters.
  • Industry experts validates the estimates which helps the company to cement the on-going research study.
  • Primary research includes online surveys, face-to face interviews, and telephonic interviews.

The primary research is conducted with the ecosystem players including, but not limited to:

  • Raw Material Suppliers
  • Manufacturers
  • System Integrators
  • Distributors
  • End-users

Subscribe Newsletter

Kindly subscribe for our latest news & articles.